- 2 Updated Systematic Review
- 3 Running Title: COVID-19 and Parkinson's Disease
- 4 **Authors:** Vikash Jaiswal^{1,2}, Danah Alquraish¹, Zouina Sarfraz*^{1,3}, Shavy Nagpal⁴, Prakriti Singh
- 5 Shrestha⁴, Dattatreya Mukherjee**⁵, Prathima Guntipalli¹, Azza Sarfraz^{1,6}, Diana F Sánchez
- 6 Velazco⁷, Arushee Bhatnagar¹, Saloni Savani¹, Elmjedina Halilaj¹, Samir Ruxmohan⁸, Wilson
- 7 Cueva⁸

17

- 8 Institutions:
- 9 1. Larkin Health System, South Miami, FL, USA
- 10 2. AMA School of Medicine, Makati, Philippines
- 11 3. Fatima Jinnah Medical University, Lahore, Pakistan
- 12 4. The Research Institute of St. Joe's Hamilton, ON, Canada
- 5. International School, Jinan University, P.R China
- 14 6. Aga Khan University, Karachi, Pakistan
- 7. Cayetano Heredia Peruvian University, Lima, Peru
- 8. Department of Neurology, Larkin Community Hospital, South Miami, FL, USA
- 18 *Corresponding Author: Zouina Sarfraz MBBS, Division of Research and Academic Affairs,
- 19 Larkin Health System, 7031 SW 62nd Avenue South Miami, FL 33143, USA. Email:
- 20 zouinasarfraz@gmail.com
- **Medrxiv Corresponding: Dattatreya Mukherjee, MBBS Student, Jinan University, P.R China
- 22 Dattatreyamukherjee4u@outlook.com
- 24 #All Authors have Contributed Equally and Significantly
- 25 **Conflicts of interest:** All authors declare no conflict of interest.
- **Funding:** None obtained.
- 27 Acknowledgments: We would like to acknowledge Samia Jahan, Madiha Zaidi, Wanessa
- 28 Matos, Sana Javed, Asma Mohammadi, and Sujan Poudel for their early contributions. All

- 29 authors are thankful to Jack Michel, and the Larkin Health System for boosting scholarly
- 30 research pursuits.
 - Abstract

- **Background**: COVID-19 has affected global communities with multiple neurological complications in addition to other critical medical issues. COVID-19 binds to the host's angiotensin-converting enzyme2 (ACE2) receptors, which are expressed in the neurons and glial cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors are abundantly expressed on dopamine neurons, which may worsen the prognosis of motor symptoms in Parkinson's disease (PD). SARS-CoV-2 may lead to an indirect response via immune-mediated cytokine storms and propagate through the CNS leading to damage. PD is also been associated with certain post-viral infections apart from COVID-19, such as HSV, Influenzavirus A, Measles virus, Cytomegalovirus, and Mumps.
- **Objective:** In this systematic review, we aim to provide a thorough analysis of associations between COVID-19 and neurological outcomes for patients with PD.
- Methods: Using PRISMA statement 2020, a systematic review was conducted to isolate confirmed COVID-19 patients and analyze the PD-associated neurological outcomes. A systematic literature search was conducted using the following databases: PubMed, Science Direct, Google Scholar, and Cochrane databases. The following keywords were used "COVID19, SARS-CoV-2, Parkinson's disease, Pandemic, Mortality." A modified Delphi process was employed to include the studies and ensure that the clinical outcome measures were addressed.
- **Results**: Of the 355 records located during the initial round of screening, 16 were included in the final synthesis. Of PD patients who tested positive for SARS-CoV-2, worsening motor symptoms and other viral-associated symptoms were reported. These symptoms included bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and legs. Encephalopathy was presented in two of the included studies. Increased mortality rates were identified for hospitalized patients due to COVID-19 and PD as compared to other patient groups, albeit with limited generalizability due to high bias of included studies.
- **Conclusion**: Patients with PD may experience substantial worsening of motor and non-motor symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical studies in the future ought to explore the disease severity and neurological outcomes in COVID-19 positive patients with PD as compared to non-PD patients, in addition to understanding the role of ACE2 in increased vulnerability to contracting the infection and as a treatment modality.
- **Keywords**: COVID-19, Parkinson's disease, SARS-CoV-2, Neurological, ACE2

1. Introduction

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

At the onset of the coronavirus disease (2019) pandemic on 31 December 2019, many reports found that SARS-CoV-2 primarily caused pneumonia-like symptoms ¹. This virus emerged as a global threat and a public health emergency of imminent concern across countries worldwide, with exponential transmission capability. As of May 25, 2021, there have been 167 million confirmed cases of COVID-19, with reported deaths up to 3.47 million globally ². COVID-19 belongs to a novel member of the coronaviridae family named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)³. Coronaviruses are enveloped positive singlestranded RNA viruses, and the 3' terminal contains structural proteins. The Spike (S) protein allows the virus to fuse to host cell membranes in proximity to infected and uninfected cells ⁴. A surge in the levels of cytokines (TNF $\square \alpha$, IL $\square 6$, IL $\square 8$, and IL $\square 10$) have been reported, leading to a suppression of T-cell response ⁵. To date, a multitude of studies have assessed the role of angiotensin-converting enzyme2 (ACE2) receptors in increasing vulnerability of hosts, however, there is a dearth of analysis on the role of ACE inhibitors in treating Parkinson's disease (PD) patients. In this systematic review, we aim to provide an updated, thorough analysis of associations between COVID-19 and neurological outcomes for patients with PD.

Coronavirus disease (2019) has prompted many challenges in global healthcare systems due to its unpredictability and unique manifestations in 1) pulmonary, 2) neurological, 3) cardiovascular, 4) gastrointestinal, and 5) hematological systems. The scientific literature confirms the presence of SARS-CoV-2 in CSF, in addition to respiratory, fecal, and blood

samples. In about 36.4% of cases, neurological findings have been identified, ranging from dizziness, headache, hyposmia, hypogeusia, dysphagia, muscle pain, seizures, and loss of consciousness ⁶. COVID-19 also influences socializing factors such as the surge in isolation-induced neurological effects, limited social activities possibly leading to short or long-term neuropsychiatric disorders.

94

95

96

97

98

99

100

101

102

103

104

105

106

We hypothesize that COVID-19 induced lockdowns, self-isolation, and the fears associated with contracting disease accentuate neuro-psychiatric problems such as depression and cognition. **Figure 1** illustrates motor and non-motor manifestations in addition to autonomic manifestations that are pertinent in the assessment of the clinical outcomes of confirmed positive PD patients. Given the dearth of data, we aim to provide a comprehensive and updated systematic review to guide clinical care and practice in understanding the effects of COVID-19 on Parkinson's disease.

Parkinson's Disease Clinical Manifesations Motor manifestations Non-motor manifestations 1. Resting tremors 1. Hypotensive episodes 1. Cognitive adverse 2. Rigidity effects 2. Erectile dysfunction 3. Bradykinesia 2. Neuropsychiatric 3. Bladder complications 4. Postural instability complications 3. Depression 4. Apathy

Figure 1. Clinical manifestations of Parkinson's disease.

2. Methodology 2.1. Search strategy Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, a systematic literature search was performed from December 2019 through May 2021 ⁷. The following set of keywords were used, employing the Boolean (and/or) logic: "COVID19", "SARS-CoV-2", "Parkinson's disease," "Pandemic," "Mortality." We searched the following databases, namely, PubMed, Cochrane, Science Direct, EMBASE, and Google Scholar. A modified Delphi approach was utilized to include studies and ensure that the clinical outcome measures are identified in a systematic and unanimous order in the included studies ⁸. The PRISMA flowchart is illustrated in Figure 2.




Figure 2. PRISMA Flowchart.

2.2. Study selection

We included studies with confirmed COVID-19 disease who had a history of Parkinson's disease. Only studies published in English and with open access availability were included. In total, 355 records were located during the initial round of screening. During this round of screening, all authors scanned the abstracts and titles independently, which led to the location of

155 records. In the second screening round, full-text records were screened, and 125 articles that met the exclusion criteria were removed. During the third screening round, 84 records were screened for eligibility. In total, 35 records were excluded as non-PD patient groups were present, 16 records had incomplete data for sourcing, and 16 of the full-text records present with post-COVID-19 PD development, which met the exclusion criteria. Finally, 16 articles were included in the qualitative synthesis.

2.3. Eligibility criteria

The inclusion criteria for studies and the target population consisted of 1) COVID-19 patients with Parkinson's disease, 2) patients diagnosed with Parkinson's disease before COVID-19 infection, 3) age group > 21 years old, 4) male and/or female, and 5) available articles in English language only. Studies were excluded if they met one or more of the following criteria 1) -COVID-19 negative PD patients, 2) studies on pregnant women, 3) the pediatric population, 4) crossover study design, 5) commentaries/perspective pieces.

2.4. Data extraction and synthesis

The following data were extracted from eligible studies: serial number, author and year, study design, sample size, gender, age, comorbidities, disease duration, PD outcomes, COVID-19 associated symptoms. A shared spreadsheet was used to input data, which was extracted independently by three authors for analysis and cumulative result interpretation (V.J., D.A., S.N.). The fourth reviewer (Z.S.) solved any discrepancies in data extraction and reach a consensus in case of any disagreements.

Quality assessment was conducted by two authors (V.J. and Z.S.), who independently assessed the (1) criteria of diagnosis of COVID-19 patients, (2) confirmed diagnosis of PD before the COVID-19 pandemic, (3) PD sequelae in the included studies. A descriptive analysis

was conducted and presented for the included studies. Percentages and means were presented. Frequent outcomes were reported if they have a frequency of at least 5% or more in the included studies. The term PD complications were based on the motor, non-motor, and autonomic complications mentioned in **Figure 1**.

2.5. Role of Funding

No funding was obtained for this study.

3. Results

Of the 355 records identified during the first round of screening, 16 studies comprising, 7 (43.8%) were case reports and case series, 4 (25%) case-control studies, 2 (12.5%) cross-sectional, 2 (12.5%) cohort and 1 (6.25%) retrospective study were added (**Figure 3**) ⁹¹⁰ ¹¹¹²¹³¹⁴¹⁵¹⁶¹⁷¹⁸¹⁹²⁰²¹²²²³²⁴. In total, a synthesis of 1290 PD patients with COVID-19 and the characteristics of all included studies are presented in **Table 1**.




Figure 3. Types of studies included in the systematic review.

Male gender was predominant in 10 studies ⁹¹⁰¹¹¹²¹³¹⁴¹⁵¹⁶¹⁷¹⁸ and female gender was the predominant one in 6 studies ¹⁷¹⁹²⁰²¹²²²³. Of the available patient data, the cumulative mean of age in years of included patients was 76.9 years. The average disease duration spanned 11 years

before the incidence of COVID-19 disease. Majority of the included patients presented with comorbid conditions, comprising of hypertension ⁹¹³¹⁵¹⁶²⁰²¹²³²⁴, diabetes ¹⁰¹²¹⁶¹⁸¹⁹²⁰²¹, obesity ⁹, dyslipidemia ²¹, cardiovascular disease ⁹¹⁰¹⁴¹⁵¹⁹²⁰²¹²⁴, immunocompromised ⁹¹⁵²⁴, COPD ⁹¹³¹⁴¹⁸, asthma ¹⁸, chronic renal and liver diseases ¹⁸¹⁹²⁴. Of the PD patients that were tested and positive infection with SARS-CoV-2, worsening of motor symptoms ⁹¹⁰¹¹¹⁴¹⁵¹⁶¹⁸¹⁹²¹²³ including bradykinesia, tremors, gait disturbances, delirium, and dementia ¹³¹⁹ were noted; severe spasms of the arms and legs ²² were found, with individual study percentages of motor symptoms ranging from 19% to 100%, along with other COVD-19 symptoms. Encephalopathy was also one of the major symptoms, which presented in 2 (12.5%) of the 16 studies ^{in 2023}. Mortality rates for PD patients with COVID-19 who were hospitalized ranged from 5.7% to 100% ⁹¹⁰¹¹¹²¹³¹⁴¹⁵¹⁶¹⁸¹⁹²⁰²¹²²²⁴. The mortality was notably 100% due to the inclusion of case reports.

4. Discussion

To our best understanding, this is the first systematic review to assess clinical outcomes of Parkinson's disease (PD) in confirmed COVID-19 patients with a pre-pandemic PD diagnosis. Wide varieties of neurological consequences have been reported in scientific literature among COVID-19 positive patients ²⁵²⁶²⁷²⁸²⁹³⁰³¹³²³³. Neurological symptoms comprised of the following include those associated with core dysfunction (fatigue, headache, confusion, stroke ³⁴, dizziness, syncope ³⁵, seizure, anorexia, and insomnia) ³⁶³⁷³⁸, central-peripheral mixture (Guillain Barre syndrome) ³⁹, enteric, or peripheral nervous systems dysfunction (anosmia, ageusia, myoclonus ⁴⁰, neuropathic pain, and myalgia) ⁴¹. The increase in hospital admission and mortality rates in PD and other chronic neurological diseases during the COVID-19 pandemic is of imminent concern as the long-term sequelae are currently undetermined. Most neurological diseases, including PD, are dose-dependent on prescribed medications for symptomatic management. With

In this systematic review, we included studies with COVID-19 positive patients with a prior history of Parkinson's disease. The most common manifestations due to COVID-19 in PD patients were found to be motor dysfunction. The majority of the studies showed a common motor deficit domain in the range of moderate to severe. Some of the patients presented with delirium, dementia, and encephalopathy among other COVID-19 complications. We posit that this may be related to the ACE2 mechanism in the nervous system. It is postulated that SARS-CoV-2 enters the cell, increases the activity of T cells, causing vasodilation, thrombosis, and hypoxemia, which may then lead to stroke and seizures. One theory supports the effect of the virus by stating that SARS-COV-2 attacks ACE 2 receptors in a multi-organ manner, targeting the brain. A study found that ACE2 receptors act locks on cells and the SARS-CoV-2 spike proteins act rapidly multiply on entering the cells. These ACE2 receptors control tissues in the eye, reproductive system, renal-excretory, digestive, and respiratory system, and 21 different regions of the brain, which require further deliberation in PD patients ⁴³.

We found that the average age of all participants was 76.9 years with a male predominance, in addition to a prior disease duration of 11 years. The majority of the patients reported the presence of other comorbidities, of which the following were the most common: hypertension, diabetes, obesity, dyslipidemia, cardiovascular disease, immunocompromised, COPD, asthma, chronic renal and chronic liver diseases. Documented COVID-19 neurological complications include stroke, especially in younger patients, reflecting the hypercoagulable state, leukoencephalopathy, and hemorrhagic leukoencephalopathy. Although direct encephalitis was

documented, it is rare but does occur. Further, cranial neuropathies are also infrequent but include the loss of sense of smell (cranial nerve 1) and Bell's palsy (cranial nerve 7) ⁴⁴. There have been neurocognitive signs, particularly in older age groups that warrant further associations to PD symptoms, clinical care, and management in the short and long term.

5. Limitations

We had certain limitations. The first included the presence of confounder factors. These related to the finding that multiple studies of patients with elderly PD patients had other comorbidities, possibly leading to an overrepresentation of findings. Secondly, the duration of PD and the severity of the pre-pandemic symptoms possibly influenced the synthesis of clinical outcomes due to COVID-19 infection. Thirdly, pertinent information, including prior and current medications and compliance to treatment was lacking, leading to a lack of generalized recommendations for PD and COVID-19 clinical care. While the inclusion of case reports may deviate from generalizations in our findings, we believe they are pertinent for long-term PD patients with acquired COVID-19 infection.

6. Conclusion

COVID-19 has a peaked mortality rate in older age groups, compounded with comorbid conditions. The CNS is increasingly susceptible to SARS-CoV-2, deteriorating neurological findings, particularly in patients with PD. We find that motor dysfunction, delirium, dementia, severe spasms of arms and legs, and encephalopathy are pertinent clinical findings in PD patients and ought to be addressed in current care and practice. The susceptible groups of COVID-19 positive patients with a history of PD are elderly males with 10 years or longer duration of illness and other comorbid conditions. It is still unclear how SARS-CoV2 affects the long-term health

- of the nervous system in PD patients. It is recommended that healthcare practitioners address
- 245 diminished neurological outcomes, changes in hospital stay, and raised mortality in PD patients.

7. References

246

- 248 1. Wu, Y. C., Chen, C. S. & Chan, Y. J. The outbreak of COVID-19: An overview. *Journal*
- 249 of the Chinese Medical Association (2020) doi:10.1097/JCMA.000000000000270.
- 250 2. WHO. WHO Coronavirus Disease Dashboard. WHO.int (2021).
- 3. Favalli, E. G. et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close!
- 252 Autoimmunity Reviews (2020) doi:10.1016/j.autrev.2020.102523.
- 253 4. Umakanthan, S. et al. Origin, transmission, diagnosis and management of coronavirus
- disease 2019 (COVID-19). Postgraduate Medical Journal (2020)
- 255 doi:10.1136/postgradmedj-2020-138234.
- 256 5. Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C. & Melguizo-
- 257 Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
- 258 *Cytokine and Growth Factor Reviews* (2020) doi:10.1016/j.cytogfr.2020.06.001.
- 259 6. Bhidayasiri, R., Virameteekul, S., Kim, J. M., Pal, P. K. & Chung, S. J. COVID-19: An
- early review of its global impact and considerations for parkinson's disease patient care.
- 261 *Journal of Movement Disorders* (2020) doi:10.14802/jmd.20042.
- 262 7. Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting
- 263 systematic reviews. *The BMJ* (2021) doi:10.1136/bmj.n71.
- 8. Sarfraz, A. *et al.* Randomized controlled trials of remdesivir in hospitalized coronavirus
- disease 2019 patients: A meta-analysis. *Turkish J. Emerg. Med.* (2021) doi:10.4103/2452-
- 266 2473.309139.

- 9. Cilia, R. et al. Effects of COVID-19 on Parkinson's Disease Clinical Features: A
- Community-Based Case-Control Study. *Mov. Disord.* (2020) doi:10.1002/mds.28170.
- 269 10. Del Prete, E. et al. Prevalence and impact of COVID-19 in Parkinson's disease: evidence
- from a multi-center survey in Tuscany region. J. Neurol. (2020) doi:10.1007/s00415-020-
- 271 10002-6.
- 272 11. Zhai, H. *et al.* Characteristic of Parkinson's disease with severe COVID-19: a study of 10
- 273 cases from Wuhan. *J. Neural Transm.* (2021) doi:10.1007/s00702-020-02283-y.
- 274 12. Lo Monaco, M. R., Colacicco, G., Marotta, J. & Bentivoglio, A. R. An educational case
- series of Parkinson's disease during the COVID-19 pandemic. *Revue Neurologique* (2021)
- 276 doi:10.1016/j.neurol.2020.07.007.
- 277 13. Fasano, A. et al. Predictors of COVID-19 outcome in Parkinson's disease. Park. Relat.
- 278 *Disord.* (2020) doi:10.1016/j.parkreldis.2020.08.012.
- 279 14. Filatov, A., Sharma, P., Hindi, F. & Espinosa, P. S. Neurological Complications of
- 280 Coronavirus Disease (COVID-19): Encephalopathy. *Cureus* (2020)
- 281 doi:10.7759/cureus.7352.
- 282 15. Brown, E. G. et al. The Effect of the COVID-19 Pandemic on People with Parkinson's
- 283 Disease. J. Parkinsons. Dis. (2020) doi:10.3233/JPD-202249.
- 284 16. Kobylecki, C., Jones, T., Lim, C. K., Miller, C. & Thomson, A. M. Phenomenology and
- Outcomes of In-Patients With Parkinson's Disease During the Coronavirus Disease 2019
- 286 Pandemic. *Movement Disorders* (2020) doi:10.1002/mds.28205.
- 287 17. Lo Monaco, M. R., Bentivoglio, A. R., Fusco, D., Calabresi, P. & Piano, C. Subacute
- onset dystonia in a woman affected by Parkinson's disease following SARS-COV-2
- infection. Clin. Park. Relat. Disord. (2021) doi:10.1016/j.prdoa.2020.100082.

- 290 18. Antonini, A., Leta, V., Teo, J. & Chaudhuri, K. R. Outcome of Parkinson's Disease
- Patients Affected by COVID-19. *Movement Disorders* (2020) doi:10.1002/mds.28104.
- 292 19. Vignatelli, L. et al. Risk of Hospitalization and Death for COVID-19 in People with
- 293 Parkinson's Disease or Parkinsonism. Mov. Disord. (2021) doi:10.1002/mds.28408.
- 294 20. Artusi, C. A. et al. COVID-19 in Parkinson's disease: Report on prevalence and outcome.
- 295 Parkinsonism and Related Disorders (2020) doi:10.1016/j.parkreldis.2020.09.008.
- 296 21. Santos-García, D. et al. Impact of Coronavirus Disease 2019 Pandemic on Parkinson's
- Disease: A Cross-Sectional Survey of 568 Spanish Patients. *Mov. Disord.* (2020)
- 298 doi:10.1002/mds.28261.
- 299 22. Sainz-Amo, R. et al. COVID-19 in Parkinson's disease: what holds the key? J. Neurol.
- 300 (2020) doi:10.1007/s00415-020-10272-0.
- 301 23. Li, J. et al. Management of a Parkinson's disease patient with severe COVID-19
- 302 pneumonia. Ther. Adv. Chronic Dis. (2020) doi:10.1177/2040622320949423.
- 303 24. de Marcaida, J. A. et al. Clinical characteristics of coronavirus disease 2019 (COVID-19)
- among patients at a movement disorders center. *Geriatr.* (2020)
- 305 doi:10.3390/GERIATRICS5030054.
- 306 25. Prasad, S. et al. Parkinson's Disease and COVID-19: Perceptions and Implications in
- Patients and Caregivers. *Movement Disorders* (2020) doi:10.1002/mds.28088.
- 308 26. Helmich, R. C. & Bloem, B. R. The Impact of the COVID-19 Pandemic on Parkinson's
- Disease: Hidden Sorrows and Emerging Opportunities. *Journal of Parkinson's Disease*
- 310 (2020) doi:10.3233/JPD-202038.
- 311 27. Stoessl, A. J., Bhatia, K. P. & Merello, M. Movement Disorders in the World of COVID-
- 312 19. *Movement Disorders* (2020) doi:10.1002/mds.28069.

- 313 28. Papa, S. M. et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and
- 314 Movement Disorders. Movement Disorders Clinical Practice (2020)
- 315 doi:10.1002/mdc3.12953.
- 316 29. Mao, L. et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus
- 317 Disease 2019 in Wuhan, China. *JAMA Neurol.* (2020) doi:10.1001/jamaneurol.2020.1127.
- 318 30. Esposito, G. et al. Can the enteric nervous system be an alternative entrance door in
- 319 SARS-CoV2 neuroinvasion? *Brain, Behavior, and Immunity* (2020)
- 320 doi:10.1016/j.bbi.2020.04.060.
- 31. Li, Y. C., Bai, W. Z. & Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may
- play a role in the respiratory failure of COVID-19 patients. *Journal of Medical Virology*
- 323 (2020) doi:10.1002/jmv.25728.
- 32. Moriguchi, T. et al. A first case of meningitis/encephalitis associated with SARS-
- 325 Coronavirus-2. *Int. J. Infect. Dis.* (2020) doi:10.1016/j.ijid.2020.03.062.
- 326 33. Poyiadji, N. et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy:
- 327 Imaging features. *Radiology* (2020) doi:10.1148/radiol.2020201187.
- 328 34. Beyrouti, R. et al. Characteristics of ischaemic stroke associated with COVID-19. Journal
- of Neurology, Neurosurgery and Psychiatry (2020) doi:10.1136/jnnp-2020-323586.
- 35. Ebrille, E. et al. Syncope as the presenting symptom of COVID-19 infection. Hear. Case
- 331 Reports (2020) doi:10.1016/j.hrcr.2020.04.015.
- 332 36. Lechien, J. R. et al. Clinical and epidemiological characteristics of 1420 European patients
- with mild-to-moderate coronavirus disease 2019. J. Intern. Med. (2020)
- doi:10.1111/joim.13089.
- 335 37. Zanin, L. et al. SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta

336 Neurochir. (Wien). (2020) doi:10.1007/s00701-020-04374-x. 337 38. Rogers, J. P. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the 338 339 COVID-19 pandemic. The Lancet Psychiatry (2020) doi:10.1016/S2215-0366(20)30203-340 0. 341 Toscano, G. et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N. Engl. J. 39. 342 Med. (2020) doi:10.1056/nejmc2009191. 343 40. Rábano-Suárez, P. et al. Generalized myoclonus in COVID-19. Neurology (2020) doi:10.1212/WNL.0000000000009829. 344 Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel 345 41. 346 Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J. Am. Med. Assoc. (2020) 347 doi:10.1001/jama.2020.1585. 348 42. Guo, D. et al. Influence of the COVID-19 Pandemic on Quality of Life of Patients with 349 Parkinson's Disease. Parkinsons. Dis. (2020) doi:10.1155/2020/1216568. 350 43. Lukiw, W. J., Pogue, A. & Hill, J. M. SARS-CoV-2 Infectivity and Neurological Targets 351 in the Brain. Cell. Mol. Neurobiol. (2020) doi:10.1007/s10571-020-00947-7. 352 44. Costello, F. & Dalakas, M. C. Cranial neuropathies and COVID-19: Neurotropism and 353 autoimmunity. Neurology (2020) doi:10.1212/WNL.000000000009921. 354 355 356 357

No	Author	Study Design	Sample (N) PD	Males, %	Age, Mean	Comorbidities %	Disease duration , mean	Outcomes	PD related symptoms With COVID %
1	Cilia R et al, 2020	Case- control	12 cases 36 control	41.7 % cases 41.7% controls	65.5 years cases 66.3 years control	8.3% COPD 33.3 HTN 8.3% obesity 8.3% cardiopathy 16.7 % cancer 8.3% immuno- compromised	6.3 years cases 6.1 years control	50% affected by COVID-19 (cases group); 0% affected by COVID-19 in control group, 8.3% hospitalized	Worsening of motor symptoms
2	Del Prete, Eleonora, et al.2020	Case-control	7 cases 14 control	57.2% cases 57.2 % control	75.7 years cases versus 75 years control	Cases: 71.5% HTN 42.8% diabetes 28.5% cardiomyopathy 14.2% malignancies	9.3 years cases 8.9 years control	13 % mortality 14% case fatality	30% worsening

3	Hainque E et al, 2020	Case report	2	50 %	77.5	HTN	22y	100 %	100% worsening
4	Lo Monaco MR et al, 2020	Case series	5	66.6 %	74.2	20% Chronic Renal failure 20% Diabetes hypertension	NA	20% case fatality	60% Worsening
5	Fasano, Alfonso, et al. 2020	Case- control survey	105	52.4%	70.5	Obesity 18.1 % HTN 41.9% COPD 5.6% Diabetes 7.6% Cancer .9 %	9.9 y	17.1% hospitalized 5.7 % mortality	
6	Filatov, Asia, et al.202I	Case report	1		74	atrial fibrillation cardioembolic stroke COPD	NA	Icu hospitalization Poor prognosis	Encephalopat hy
7	Brown EG, et al,	Cross sectiona	51	47 %	65	Immunocompromis ed 22%	0–3y□ 21	9.8% Hospitalized	55 % worsening

	2020	1				Heart Disease 20% HTN 25%	3–6y 12 6–9y 9	3.9% ICU 2% Ventilator	18 % new PD symptoms
						Lung disease 14%	>9y 9	270 Ventifutor	symptoms
8	Kobylecki C et al 2020	Cohort, observat ional	58	62.5 %	78.3	Diabetes 8% HTN 38%	9.5	22.4% Mortality rate	69% Delirium 54% Dementia
9	Lo Monaco MR et al, 2021	Case report	1	0%	58	NA	8 y	NA	severe spasms of arms and legs.
10	Antonini et al 2020	case series	10	60 %	78.3	Diabetes Orthostatic hypotension CHF, COPD Asthma IHD, CKD, dementia, osteoporosis	12.7 y	40% mortality rate	Worsening of mobility with fall Worsening of motor symptoms Worsening of anxiety

						anxiety disorder	l		
11	Vignatelli et al, 2020	cohort	696 PD 184 parkinson ism control 8590	58.8 & PD 57.1 parkinson ism 58.2 control	75 PD 80.5 PS Control 76.0	PD and PS 22.6 % cardiomyopathies 14.6 % Cerebrovascular disease 8.5 % Chronic pulmonary disease .3 % Liver disease 5 %Renal disease 10% DM 8.5% malignancies	NA	Hospitalization 0.6% PD 3.3% PS 0.7% control Mortality rate 35.1% in all group	PD: 72.8% Tremo r 80,4% Bradykinesia 81.6% Clinical features at onset unilateral PS: 52.5% Tremo r 89.2 % Bradykinesia 52.5% Clinical

									features at onset unilateral
12	Artusi CA,et al, 2020	multiple case reports	8	62.5%	74	HTN diabetes, depression lung neoplasm Atrial fibrillation	12.2 y	75% mortality rate	50% worsening of PD symptoms
13	Diego Santos- García et al,	cross- sectiona 1	15	47.1%	76.3	26.7% HTN 20% DM 64.3% Dyslipidemia 13.3% Cardiomyop athy 6.7% Valvular cardiomyopathy 20% Cardiac Arrhythmia 6.7% Cardiac Insufficiency 14.3% Pulmonary	NA	33.3% Hospitalized	worsening of symptoms 47.7% bradykinesia 41.4% sleep problems 40.7% rigidity 34.5% gait disturbances 31.3%

						disease 6.7% smoking			anxiety 28.5% pain 28.3% fatigue 27.6% Depression 20.8% tremor
14	R Sainz Amo et al. 2020	Case Control	Case: 33 Control:1 72	5 59	Case:75.9 Control: 73.9	36% Dementia	Case: 8.9 Control8	54% hospitalization 21% mortality rate	NA
15	Jing li et al. 2020	Case	1	Female	85	HTN Stroke	6 y		worsening motor symptoms. Encephalopat hy
16	De Marcaida et al 2020	Retrosp	36 22 PD	64 %	74.5	HTN cardiovascular	16.2 y	67% hospitalization 36% mortality	75% Alteration

			disease		mental status
			renal disease, diabetes		19 % worsening of their
			chronic lung disease		Movement abnormality
			immunosuppressio n		31% worsening
					mobility

Table 1. Characteristics of included studies.